Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:10:33.179Z.
Calculation as of: 2026-10-06T15:10:33.179Z.
Quote observation: 2026-10-06T15:10:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f2d634a7ba4b3af29dc0bd0f7aeccfce6021194a57d8f55324c803ee9ac920cb
PEG RATIO
N/A
Acurx Pharmaceuticals, Inc.
Market Cap
$5.57M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Acurx Pharmaceuticals, Inc. (ACXP) | $5.57M | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.68M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | N/A |
| Lucyd, Inc (LUCY)vs › | $5.80M | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.84M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.26M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.23M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.17M | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.99M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
